These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2879481)

  • 21. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography.
    Wolkin A; Jaeger J; Brodie JD; Wolf AP; Fowler J; Rotrosen J; Gomez-Mont F; Cancro R
    Am J Psychiatry; 1985 May; 142(5):564-71. PubMed ID: 3872603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia.
    Hazlett EA; Buchsbaum MS; Kemether E; Bloom R; Platholi J; Brickman AM; Shihabuddin L; Tang C; Byne W
    Am J Psychiatry; 2004 Feb; 161(2):305-14. PubMed ID: 14754780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia.
    Schroder J; Buchsbaum MS; Siegel BV; Geider FJ; Lohr J; Tang C; Wu J; Potkin SG
    Schizophr Res; 1996 Mar; 19(1):41-53. PubMed ID: 9147495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia.
    Karlsson P; Farde L; Halldin C; Sedvall G
    Am J Psychiatry; 2002 May; 159(5):761-7. PubMed ID: 11986129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia.
    Shioiri T; Kato T; Inubushi T; Murashita J; Takahashi S
    Psychiatry Res; 1994 Dec; 55(4):223-35. PubMed ID: 7701036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucose metabolic rate in normals and schizophrenics during the Continuous Performance Test assessed by positron emission tomography.
    Buchsbaum MS; Nuechterlein KH; Haier RJ; Wu J; Sicotte N; Hazlett E; Asarnow R; Potkin S; Guich S
    Br J Psychiatry; 1990 Feb; 156():216-27. PubMed ID: 2317626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography.
    Elkashef AM; Doudet D; Bryant T; Cohen RM; Li SH; Wyatt RJ
    Psychiatry Res; 2000 Nov; 100(1):1-11. PubMed ID: 11090720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low frontal serotonin 2A receptor binding is a state marker for schizophrenia?
    Rasmussen H; Frokjaer VG; Hilker RW; Madsen J; Anhøj S; Oranje B; Pinborg LH; Glenthøj B; Knudsen GM
    Eur Neuropsychopharmacol; 2016 Jul; 26(7):1248-50. PubMed ID: 27179966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cerebral glucose metabolism in schizophrenia. Studies using positron-emission tomography].
    M'Rabet N; Lotstra F; Goldman S; Delvenne V; Mendlewicz J
    Acta Psychiatr Belg; 1991; 91(6):311-26. PubMed ID: 1670424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased manganese-superoxide dismutase activity in postmortem brain from neuroleptic-treated psychotic patients.
    Loven DP; James JF; Biggs L; Little KY
    Biol Psychiatry; 1996 Aug; 40(3):230-2. PubMed ID: 8830959
    [No Abstract]   [Full Text] [Related]  

  • 31. Glucose metabolic rate in schizophrenia.
    Freidman EH
    Br J Psychiatry; 1990 Jun; 156():909-10. PubMed ID: 2207532
    [No Abstract]   [Full Text] [Related]  

  • 32. Altered frontostriatal relationship in unmedicated schizophrenic patients.
    Biver F; Goldman S; Luxen A; Delvenne V; De Maertelaer V; De La Fuente J; Mendlewicz J; Lotstra F
    Psychiatry Res; 1995 Sep; 61(3):161-71. PubMed ID: 8545500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [No hypofrontality in schizophrenia demonstrated by positron emission tomography].
    Biver F; Delvenne V; Goldman S; Luxen A; De Maertelaer V; Lotstra F; Mendlewicz J
    Acta Psychiatr Belg; 1992; 92(5):261-78. PubMed ID: 1345405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of frontal D(2/3) binding potentials to cognition: a study of antipsychotic-naive schizophrenia patients.
    Fagerlund B; Pinborg LH; Mortensen EL; Friberg L; Baaré WF; Gade A; Svarer C; Glenthøj BY
    Int J Neuropsychopharmacol; 2013 Feb; 16(1):23-36. PubMed ID: 22338593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of frontal lobe epileptic foci in children using positron emission tomography.
    da Silva EA; Chugani DC; Muzik O; Chugani HT
    Epilepsia; 1997 Nov; 38(11):1198-208. PubMed ID: 9579921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NMDA Receptor Model of Antipsychotic Drug-Induced Hypofrontality.
    Krzystanek M; Pałasz A
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prefrontal lobotomy and hypofrontality in patients with schizophrenia: an integration of the findings.
    Goumeniouk AD; Clark CM
    Can J Psychiatry; 1992 Feb; 37(1):17-22. PubMed ID: 1348011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional brain imaging and aging in schizophrenia.
    Buchsbaum MS; Hazlett EA
    Schizophr Res; 1997 Oct; 27(2-3):129-41. PubMed ID: 9416643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward a brain map of auditory hallucinations.
    Cleghorn JM; Franco S; Szechtman B; Kaplan RD; Szechtman H; Brown GM; Nahmias C; Garnett ES
    Am J Psychiatry; 1992 Aug; 149(8):1062-9. PubMed ID: 1353314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia.
    Lane CJ; Ngan ET; Yatham LN; Ruth TJ; Liddle PF
    J Psychiatry Neurosci; 2004 Jan; 29(1):30-7. PubMed ID: 14719048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.